| Dr Joseph E Mumford, MD | |
|
2660 Sw 3rd St., Topeka, KS 66606 | |
| (785) 270-8880 | |
| Not Available |
| Full Name | Dr Joseph E Mumford |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 38 Years |
| Location | 2660 Sw 3rd St., Topeka, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699751792 | NPI | - | NPPES |
| 100136790C | Medicaid | KS | |
| 068002048 | Other | KS | MEDICARE PTAN |
| 100136790A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 04-24175 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stormont Vail Hospital | Topeka, KS | Hospital |
| Great Plains Of Sabetha | Sabetha, KS | Hospital |
| Nemaha Valley Community Hospital | Seneca, KS | Hospital |
| Wamego Health Center | Wamego, KS | Hospital |
| Holton Community Hospital | Holton, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cotton O'neil Clinic Revocable Trust | 5496659195 | 576 |
News Archive
Intarcia Therapeutics, Inc. today announced the closing of a $225 million synthetic royalty financing with an equity conversion option at a $5.5 billion Company valuation. Plans are to use these funds to accelerate the initiation of additional head-to-head comparative and switch studies of ITCA 650 vs. leading oral and injectable type 2 diabetes therapies.
The Christian Science Monitor reports that the health overhaul is resting in the GOP's crosshairs. The ultimate defense to the repeal effort is the presidential veto pen. Even with a new majority in the House come January, Republicans concede that winning a repeal vote in the Democratic-controlled Senate is unlikely and the two-thirds needed to override a presidential veto, well out of reach.
Amity Manning, assistant professor of biology and biotechnology, has received a three-year, $300,000 award from the Smith Family Awards Program for Excellence in Biomedical Research.
There is growing awareness that air pollutants are playing a critical role in the development of neurodegenerative diseases.
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.
› Verified 3 days ago
| Entity Name | Cotton O'neil Clinic Revocable Trust |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811944457 PECOS PAC ID: 5496659195 Enrollment ID: O20031124000674 |
News Archive
Intarcia Therapeutics, Inc. today announced the closing of a $225 million synthetic royalty financing with an equity conversion option at a $5.5 billion Company valuation. Plans are to use these funds to accelerate the initiation of additional head-to-head comparative and switch studies of ITCA 650 vs. leading oral and injectable type 2 diabetes therapies.
The Christian Science Monitor reports that the health overhaul is resting in the GOP's crosshairs. The ultimate defense to the repeal effort is the presidential veto pen. Even with a new majority in the House come January, Republicans concede that winning a repeal vote in the Democratic-controlled Senate is unlikely and the two-thirds needed to override a presidential veto, well out of reach.
Amity Manning, assistant professor of biology and biotechnology, has received a three-year, $300,000 award from the Smith Family Awards Program for Excellence in Biomedical Research.
There is growing awareness that air pollutants are playing a critical role in the development of neurodegenerative diseases.
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph E Mumford, MD 2660 Sw 3rd St., Topeka, KS 66606 Ph: (785) 270-8880 | Dr Joseph E Mumford, MD 2660 Sw 3rd St., Topeka, KS 66606 Ph: (785) 270-8880 |
News Archive
Intarcia Therapeutics, Inc. today announced the closing of a $225 million synthetic royalty financing with an equity conversion option at a $5.5 billion Company valuation. Plans are to use these funds to accelerate the initiation of additional head-to-head comparative and switch studies of ITCA 650 vs. leading oral and injectable type 2 diabetes therapies.
The Christian Science Monitor reports that the health overhaul is resting in the GOP's crosshairs. The ultimate defense to the repeal effort is the presidential veto pen. Even with a new majority in the House come January, Republicans concede that winning a repeal vote in the Democratic-controlled Senate is unlikely and the two-thirds needed to override a presidential veto, well out of reach.
Amity Manning, assistant professor of biology and biotechnology, has received a three-year, $300,000 award from the Smith Family Awards Program for Excellence in Biomedical Research.
There is growing awareness that air pollutants are playing a critical role in the development of neurodegenerative diseases.
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.
› Verified 3 days ago
Dr. Michael L Smith, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2660 Sw 3rd St, Topeka, KS 66606 Phone: 785-270-8880 | |
Dr. Michael J Schmidt, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 6001 Sw 6th Ave, Suite 200, Topeka, KS 66615 Phone: 785-233-7491 Fax: 785-233-3187 | |
Dr. John H Gilbert Ii, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 909 Sw Mulvane St, Topeka, KS 66606 Phone: 785-357-0301 Fax: 785-357-6589 | |
Dr. Peter S Lepse, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 2660 Sw 3rd St., Topeka, KS 66606 Phone: 785-354-6116 Fax: 785-354-5166 | |
Dr. Kurt R Knappenberger, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 6001 Sw 6th Ave, Suite 200, Topeka, KS 66615 Phone: 785-233-7491 Fax: 785-233-3187 | |
Dr. Michael Brenden Tilley, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2660 Sw 3rd St, Topeka, KS 66606 Phone: 785-270-8880 | |
Dr. Ryan James Tomlins, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2660 Sw 3rd St, Topeka, KS 66606 Phone: 785-270-8880 Fax: 785-270-8881 |